Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2006 > Volume 15 Number 1 January 2006 > DEVICE EVALUATION > Fifteen Years of Clinical and Echocardiographic Follow Up with the CarboMedics Heart Valve

Fifteen Years of Clinical and Echocardiographic Follow Up with the CarboMedics Heart Valve

Michel Carrier, Michel Pellerin, Arsène Basmadjian, Denis Bouchard, Louis P. Perrault, Raymond Cartier, Pierre Pagé, Philippe Demers, Yves Hébert

Montreal Heart Institute, Department of Surgery and Department of Medicine, Montreal, Quebec, Canada

Background and aim of the study: Mechanical prostheses are used in young patients, the CarboMedics valve having been the mechanical valve of choice of the present authors during the past 15 years. The study aim was to analyze long-term clinical and echocardiographic results obtained with CarboMedics mechanical valves.
Methods: A total of 2,953 patients underwent valve replacement with the CarboMedics valve between 1988 and 2004 at the Montreal Heart Institute. Patients were prospectively followed at the outpatient valve clinic. Subsequently, 1,004 patients underwent echocardiographic examinations during follow up.
Results: In total, 1,597 patients (mean age 57 ± 12 years) underwent isolated aortic valve replacement (AVR), 1,043 patients (mean age 59 ± 10 years) underwent isolated mitral valve replacement (MVR), and 313 patients (mean age 58 ± 11 years) underwent AVR+MVR. The mean five-, 10- and 15-year actuarial survival rates were 83 ± 1%, 70 ± 2% and 62 ± 3% in AVR patients, 76 ± 1%, 59 ± 2% and 40 ± 14%

in MVR patients, and 68 ± 3%, 51 ± 4% and 33 ± 9% in AVR+MVR patients. The mean 15-year freedom from cerebral embolism, hemorrhage and reoperation was 95 ± 1%, 97 ± 1% and 95 ± 1% in AVR patients, 92 ± 1%, 97 ± 1% and 93 ± 1% in MVR patients, and 94 ± 2%, 93 ± 2% and 91 ± 4% in AVR+MVR patients. AVR patients had a mean aortic gradient of 29 ± 14, 20 ± 8, 18 ± 7, 16 ± 7, 12 ± 5 and 11 ± 5 mmHg with 19, 21, 23, 25, 27 and 29 mm prostheses, respectively (p = 0.001). MVR patients had a mean mitral gradient of 5.3 ± 3, 4.9 ± 2.2, 4.6 ± 2, 4.4 ± 2.9 and 4.9 ± 1.8 mmHg with 25, 27, 29, 31 and 33 mm prostheses, respectively (p = 0.63).
Conclusion: Patient survival and valve-related complications were satisfactory at 15 years after valve replacement with the CarboMedics valve. Mean aortic gradients were high with the 19-mm aortic prostheses, but all other valve sizes showed good hemodynamic performance, as measured using transthoracic echocardiography.
The Journal of Heart Valve Disease 2006;15:67-72

Fifteen Years of Clinical and Echocardiographic Follow Up with the CarboMedics Heart Valve

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.